These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18678843)

  • 1. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.
    Burgio KL; Kraus SR; Menefee S; Borello-France D; Corton M; Johnson HW; Mallett V; Norton P; FitzGerald MP; Dandreo KJ; Richter HE; Rozanski T; Albo M; Zyczynski HM; Lemack GE; Chai TC; Khandwala S; Baker J; Brubaker L; Stoddard AM; Goode PS; Nielsen-Omeis B; Nager CW; Kenton K; Tennstedt SL; Kusek JW; Chang TD; Nyberg LM; Steers W;
    Ann Intern Med; 2008 Aug; 149(3):161-9. PubMed ID: 18678843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study.
    Urinary Incontinence Treatment Network (UITN)
    Contemp Clin Trials; 2007 Jan; 28(1):48-58. PubMed ID: 16919506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women.
    Zimmern P; Litman HJ; Mueller E; Norton P; Goode P;
    BJU Int; 2010 Jun; 105(12):1680-5. PubMed ID: 19912207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
    Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
    Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
    Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
    Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).
    Siami P; Seidman LS; Lama D
    Clin Ther; 2002 Apr; 24(4):616-28. PubMed ID: 12017406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates and predictors of patient satisfaction with drug therapy and combined drug therapy and behavioral training for urgency urinary incontinence in women.
    Goode PS; Burgio KL; Kraus SR; Kenton K; Litman HJ; Richter HE;
    Int Urogynecol J; 2011 Mar; 22(3):327-34. PubMed ID: 20945064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
    Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
    J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
    Sussman D; Garely A
    Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.